Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Antoni Ribas¹, Rajarshi Sengupta², Trevan Locke², Sayyed Kaleem Zaidi², Katie M. Campbell¹, John M. Carethers³, Elizabeth M. Jaffee⁴, E. John Wherry⁵, Jean-Charles Soria⁶, and Gypsyamber D’Souza⁷; for the AACR COVID-19 and Cancer Task Force

Summary: Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

At this time of limited supply of the highly effective COVID-19 vaccines, it is important to gather the evidence on the risk of complications and death resultant from a diagnosis of COVID-19 infection in patients with cancer. After reviewing 28 publications, many of which included relevant information on fatality rates of patients with cancer who developed COVID-19 (1–28), we conclude that patients with an active cancer should be considered for priority access to COVID-19 vaccination, along with other particularly vulnerable populations with risk factors for adverse outcomes with COVID-19. This recommendation is consistent with the Advisory Committee on Immunization Practices (ACIP) within the Centers for Disease Control and Prevention (CDC). The ACIP considered multiple groups to recommend for early access to a limited COVID-19 vaccine supply and concluded that patients with cancer are at a higher risk for severe COVID-19 and should be one of the groups considered for early COVID-19 vaccination (29). Given that there are nearly 17 million people living with a history of cancer in the United States alone, it is critical to understand whether these individuals are at a higher risk to contract SARS-COV-2 and to experience severe outcomes from COVID-19.

Our review of the available literature to provide the scientific support for early access during the time of limited supplies of COVID-19 vaccines was based on a literature search for peer-reviewed publications using PubMed. We selected articles that reported either case fatality rates (CFR) or the mortality risks among SARS-COV-2–infected patients with cancer. We excluded articles with cohort sizes of fewer than 90 patients. Of 28 articles selected, 16 included one or more control cohorts, with 13 studies reporting on direct comparisons of outcomes from SARS-COV-2–infected patients with cancer with those without cancer (Supplementary Table S1; refs. 1–13). Of these 13 studies, 11 reported CFRs among patients with cancer with a SARS-COV-2 infection. Ten out of the 11 studies reported a higher CFR in patients with a SARS-CoV2 infection and cancer compared with patients with infection but no cancer (Fig. 1). Examples from studies from different parts of the world include a series from Wuhan, China, with CFRs of 22% with cancer and 11% without cancer (10); New York, USA, with CFRs of 28% with cancer and 14% without cancer (11); Louisiana, USA, with CFRs of 21% with cancer and 9% without cancer (5); and Europe, with CFRs of 22% with cancer and 14% without cancer (ref. 4; Supplementary Table S1). Three series compared outcomes among SARS-COV-2–infected patients with cancer with uninfected patients with cancer, with two reporting higher mortality in patients with cancer and COVID-19 (Supplementary Table S2; refs. 14–16).

Analysis of adjusted ratios (hazard ratio or odds ratio) confirm a greater risk for severe disease and mortality from COVID-19 in patients with cancer, with variability among series but an overall clear trend (Fig. 2). To determine whether the increased mortality from COVID-19 in patients with cancer was attributable to their underlying malignancies or any of the other factors that are associated with worse outcomes (such as advanced age or adverse comorbidities), several studies adjusted for age, sex, and comorbidities in their analyses and presented the ratios of mortality risks among patients with cancer and a SARS-COV-2 infection compared with those without cancer. Patients diagnosed with hematologic malignancies were at an especially higher risk. An example is a series from a single hospital in New York, with CFR of 37%
in patients with hematologic malignancies compared with 25% in patients with solid cancers. Additional factors such as differences in older age, advanced COVID-19 disease and hospitalizations, and overall quality of care received can all impact outcomes of COVID-19 in patients with cancer.

Nine studies did not include a control or reference group in their analysis (Supplementary Table S3; refs. 17–25). These studies reported a high CFR among SARS-COV-2-infected patients with cancer, which seems to be higher when indirectly compared with existing national or global statistics. However, it is difficult to interpret these data in the absence of an appropriate concurrent control cohort from the same hospital or health care system. The remaining three studies were meta-analyses, two of which confirmed that patients with cancer were at increased risk of fatality and severe illness due to COVID-19 when aggregating all of the available series into an overall estimate (Supplementary Table S4; refs. 26–28).

Information is limited on the effects of COVID-19 vaccination in patients with cancer. Among the 43,540 subjects enrolled in the BNT162b2 mRNA COVID-19 vaccine trial, 3.7% were reported to have cancer, with a total of five patients enrolled in the BNT162b2 mRNA COVID-19 vaccine trial, 3.7% were reported to have cancer, with a total of five patients receiving anti-CD20 or cytotoxic therapies may not demonstrate an antibody response to the COVID-19 vaccination, but because the current vaccines demonstrate a strong T-cell response, it is possible that they would still result in protective T-cell immunity. Therefore, the benefit of COVID-19 vaccination may not be adequately assessed with serologic testing in these patients.

Finally, after over a decade of clinical testing, there is currently no evidence that cancer immunotherapy with immune-checkpoint blockade increases the complications from any prior viral vaccine administration. Despite that three of the series we reviewed (5, 19, 21) reported that patients receiving cancer immunotherapies had increased risk of complications and death from COVID-19, it is now recognized that this may reflect the confluence of comorbidities and risk factors in these patients; for example, patients with lung cancer induced by cigarette smoke, who are more likely to have preexisting lung inflammatory disease, which is an adverse risk factor for COVID-19, are more likely to be treated with immune-checkpoint blockade therapies (34). This patient population reflecting several comorbidities may be particularly vulnerable and would benefit from priority vaccination. Therefore, it is reasonable to recommend that patients receiving cancer immunotherapies should be considered for priority COVID-19 vaccination regardless of receiving this therapy.

We conclude that the data in these studies support the recommendation to provide priority COVID-19 vaccination to patients with cancer due to their increased risk of mortality.
with COVID-19 infection. This recommendation should result in early vaccination to patients who are currently receiving treatment for cancer, or have an advanced cancer that may result in increased risk of complications from COVID-19, in particular for patients with hematologic malignancies and lung cancer. It is unclear whether this recommendation should be applicable to patients with a past diagnosis of cancer, as cancer survivors can be considered having the same risk as other persons with matched age and other risk factors. The fact that patients undergoing cancer treatments are in very frequent contact with health care workers increases the risk of exposure and puts the patients at the front line of our health care system.

**Authors’ Disclosures**

A. Ribas reports personal fees from Amgen (honorary), Chugai (honorary), Genentech (honorary), Merck (honorary), Novartis (honorary), Roche (honorary), Sanofi (honorary), Vedanta (honorary), Advaxis (scientific advisory board member, honorary, stock), Apricity (scientific advisory board member, honorary, stock), Arcus (scientific advisory board member, honorary, stock), Compugen (scientific advisory board member, honorary, stock), CytomX (scientific advisory board member, honorary, stock), Five Prime (scientific advisory board member, honorary, stock), Highlight (scientific advisory board member, honorary, stock), ImaginAb (scientific advisory board member, honorary, stock), Isoplexis (scientific advisory board member, honorary, stock), Kite/Gilead (scientific advisory board member, honorary, stock), Lutris (scientific advisory board member, honorary, stock), Merus (scientific advisory board member, honorary, stock), PACT (scientific advisory board member, honorary, stock), RAPT (scientific advisory board member, honorary, stock), Regnix (scientific advisory board member, honorary, stock), and Tango Therapeutics (scientific advisory board member, honorary, stock) and grants from NCI, Agilent, Bristol-Myers Squibb through Stand Up To Cancer (SU2C), the Melanoma Research Alliance, and the Parker Institute for Cancer Immunotherapy outside the submitted work. R. Sengupta, T. Locke, and S.K. Zaidi are employed by the American Association for Cancer Research. E.M. Jaffee reports grants from Bristol-Myers Squibb; personal fees from Genocea (consultation), Achilles (consultation), Dragonfly (consultation), and CSTONE (consultation); other from AbMeta (founder) and PICI (consultant); and reports grants from and is the Chief Medical Advisor for Lustgarten Foundation outside the submitted work. No disclosures were reported by the other authors.

Published first December 19, 2020.

**REFERENCES**

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Antoni Ribas, Rajarshi Sengupta, Trevan Locke, et al.
Cancer Discov  Published OnlineFirst December 19, 2020.

Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-20-1817

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2020/12/19/2159-8290.CD-20-1817.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/early/2021/01/04/2159-8290.CD-20-1817. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.